Biotech week ahead, June 11

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. Nektar Therapeutics NKTR 2.21% slumped about 42 percent, while Deciphera Pharmaceuticals Inc DCPH 2.12% has rallied about 60 percent since June 1.

Here’s a look at the upcoming week’s catalytic events.

Conferences

• 41st European Congress of Cytology – June 10-13, in Madrid, Spain
• 31st International Conference On Antiviral Research, or ICAR – June 11-15, in Porto, Portugal
• Goldman Sachs 39th Annual Global Healthcare Conference – June 12-14, in Rancho Palos Verdes, California
• Annual European Congress of Rheumatology, 2018 – June 13-16, in Amsterdam, Netherlands
• UK Oncology Forum – June 14-15, in Liverpool, U.K.
• 23rd Congress of European Hematology Association, or EHA, – June 14-17, in Stockholm, Sweden
• 52nd European Human Genetics Conference in conjunction with the European Meeting on Psychological Aspects of Genetics – June 16-19, in Milan, Italy

Clinical Trial Presentations

Chimerix Inc CMRX 3.9% is due to present Phase 1 data on its norovirus treatment candidate CMX521 at the ICAR between June 11-15. The company recently received orphan drug designation to its smallpox treatment candidate brincidofovir.

Beigene Ltd (ADR) BGNE 1.56% will present Phase 1/2 data for its Zanubrutinib, its treatment candidate for Waldenstrom’s macroglobulinemia, at the EHA on Friday.

AbbVie Inc ABBV 1.12% and Roche Holdings AG Basel ADR Common Stock RHHBY 0.81% will present Phase 3 data for Venclexta, their relapsed or refractory chronic lymphocytic leukemia, or CLL, treatment candidate, at the EHA on Saturday.

bluebird bio Inc BLUE 0.27% is due to present Phase 3 data on LentiGlobin, code named HGB-207, from a study called Northstar-2, which evaluated the pipeline candidate for non-beta0/beta0 transfusion-dependent thalassemia, at the EHA on Saturday.

IPOs

Verrica Pharmaceuticals, a clinical-stage dermatology company, is scheduled to IPO, offering 5 million shares at an estimated price range of $14 to $16. The company seeks to list its shares on the Nasdaq under the ticker symbol VRCA.

https://bit.ly/2xZpQ1g